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ABSTRACT 
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. It is caused 
by the somatic acquisition of genetic abnormalities and malignant transformation of 
immature lymphocytes in the bone marrow, most commonly of B-cell lineage. Chromosomal 
translocations are a hallmark of childhood ALL, constituting different subtypes of disease in 
terms of clinical characteristics and treatment outcomes. More than that, these gross 
chromosomal changes are often directly linked to specific disruptions at the molecular level 
through resulting fusion genes, aberrant transcriptional activation or associated structural and 
single nucleotide variants.  
The aim of this thesis was to establish the frequency and prognostic impact associated with 
the chromosomal abnormality dic(9;20)(p13.2;q11.2) in childhood B-cell precursor (BCP) 
ALL, and to better our understanding of the genetic basis underlying this disease. Thereby, 
we aimed to improve the diagnostics and risk-stratification in the context of existing anti-
leukemic treatments, while potentially highlighting new rational strategies of therapy in 
dic(9;20) and childhood ALL in general. 
In paper I we found that the dic(9;20) was present in almost five percent of BCP ALL cases, 
making it the third most common subgroup in the cohort. Furthermore, we showed that 
dic(9;20)-positive cases treated on the NOPHO ALL-2000 protocol had a lower event-free 
survival than the most common subtypes of ALL. In paper III, we designed and validated a 
method for the detection of dic(9;20) in a clinical setting using FISH. In papers II and IV, 
we characterized the genetic basis of disease in cases carrying the dic(9;20), discovering first 
that homozygous deletions of tumor suppressor CDKN2A are present in almost all cases, but 
that the heterogeneity of the translocation breakpoints did not support the consistent 
formation of a fusion gene. Further, in paper IV, through the application of multiple 
genome-wide techniques, we presented a full spectrum of acquired structural and sequence 
level variation in dic(9;20)-positive ALL, as well as the integrated analysis of DNA 
methylation, gene expression and anti-leukemic drug sensitivity. Together, these data 
revealed a genetic profile distinct from that of other ALL subtypes, not accounted for by 
individual fusion genes or single gene abnormalities alone. Importantly, we found evidence 
of altered expression of several key genes governing cell survival and programmed cell death, 
attributable to changes in promoter DNA methylation; some affecting the response to existing 
anti-leukemic agents, and others highlighting specific pathways that may be of value in 
developing new therapies. 
Together, these studies add to our understanding of the clinical relevance and underlying 
biology of dic(9;20)-positive BCP ALL and provide a basis for the rational exploration of 
new treatment options for children with this disease. 
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PREFACE 
Cancer is a disease of the genome. It is the somatic acquisition of mutations, sometimes 
acting in concert with inherited genetic variation that initiates and drives the development of 
malignant disease. The sum of these aberrations often comes to define the clinical course of 
disease and response to therapy. Resolving their constitution and origin are therefore key to 
understanding the basis of cancer and ensure adequate treatment for all patients.  
Today, more than 90 percent of children diagnosed with acute lymphoblastic leukemia (ALL) 
are cured with contemporary treatment. This is the result of careful, iterative adjustments to 
multi-agent chemotherapy protocols over the course of decades. While the treatment of 
childhood ALL is one of the foremost success stories in cancer therapy, a cure for all children 
remains elusive. Also considering today's survivors there is little reason to rest. While the 
treatment of childhood ALL in many ways is a true endeavor of personalized medicine, 
guided in large part by both patient and disease characteristics, it remains one of desperate 
imprecision. To cure all children diagnosed with ALL, avoid treatment-related toxicities, and 
identify factors predisposing to leukemia development, we need to understand the genetic 
aberrations that initiate and maintain leukemic disease.  
This thesis summarizes a series of studies on patients with childhood ALL carrying a specific 
chromosomal rearrangement, namely dic(9;20). The first part provides a general introduction 
to the field of cancer genetics and childhood ALL. The next part summarizes and discusses 
the results of our studies on dic(9;20)-positive ALL. Lastly, included are the four original 
research studies on which this thesis is based.  
 
Stockholm, April 18th 2015 
 
Vasilios Zachariadis 
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1 INTRODUCTION 
Over a decade has now passed since the initial sequencing and successful draft assembly of 
the human genome.1,2 Since then, primarily through feats of engineering and technical 
developments outside the field of biology, we have quickly gained the ability to read genetic 
sequence at a large scale, in different forms and in greater detail.3 While these advances have 
arguably only begun to impact the clinical practice of medicine as a whole, some areas of 
medical research have rapidly transformed as a result. In short, we have gained the ability to 
explore more of our genome, its expression,4 and its regulatory components5 in a larger 
number of patients. In particular, the areas of rare genetic disease and cancer have seen rapid 
gains. We now have the ability to more accurately diagnose patients and catalog a large 
amount of germline and somatic variation directly linked to the pathogenesis of disease.6–8 
1.1 CANCER IS A DISEASE OF THE GENOME 
While only a fraction of cases can be attributed to inherited genetic variation, all cancer 
results from the acquisition of somatic genetic variation, conferring proliferative and other 
selective advantages over neighboring cells.9 These events can occur in sequence over a 
longer period of time,10 or in a handful of catastrophic cellular events.11 This does not imply 
that, by being able to read the genetic changes in a cancer cell, will we gain a complete 
understanding of its biology. It does, however, present a new opportunity to study individual 
cancer types at scale, looking for recurrent mutations driving disease, some of them already 
the target of approved drugs and others possible future molecular targets.12 Sequencing tumor 
material across histologically different cancers can also reveal previously unrecognized 
principles of cancer biology.13–15  
Just as different cancers, historically defined by their tissue of origin, can be very similar at 
the genomic level, there is mounting evidence for the presence of significant genetic 
heterogeneity also within an individual tumor or population of cancer cells.16–18 This adds 
another layer of complexity, both in solid tumors when selecting therapy to prevent 
metastatic disease,18 and in hematological malignancies to avoid the emergence of treatment-
resistant clones.17 In particular, this phenomenon stipulates that rational treatments, guided by 
specific targets rather than intensity alone, are a necessity as the added selective pressure that 
is chemotherapy may in some cases only serve to worsen the course of the disease.16 
1.2 ACUTE LYMPHOBLASTIC LEUKEMIA 
ALL is a malignant disease of the bone marrow, characterized by a block in lymphoid 
differentiation and the rapid clonal expansion of immature, non-functioning immune cells of 
T- or B-cell lineage – termed lymphoblasts.19,20 This population of cells quickly overwhelms 
the normal bone marrow compartment, suppressing other lineages of the hematopoietic 
system. This gives rises to the common symptoms of acute leukemia including pallor, easy 
bruising, bleeding, fevers and infections. 
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ALL is the most common cancer affecting children worldwide.21 In Sweden this corresponds 
to between 60-80 children per year, and to about 200 in the Nordic countries as a whole.21,22 
In the USA the equivalent number is 3000 new cases per year.23 In most countries around the 
world, the incidence is remarkably consistent of 3-4 cases per 100,000 individuals, and one 
that has remained without significant change over the last decades.21,24 
1.2.1 Treatment and risk stratification of childhood ALL 
Ever since Sidney Farber and colleagues first reported transient remissions in children with 
acute leukemia following treatment with aminopterin,25 an antifolate, the development of new 
cytotoxic drugs and their efficient application has mirrored incremental gains in the treatment 
of childhood ALL (figure 1).26 
While Farber's approach was an empirical one, and raised controversy at first, it was soon 
clear that the rational evaluation of a few chemical compounds, like aminopterin, could bring 
great treatment gains to cancers of different types, and to childhood leukemias in particular.27 
What was also clear to researchers and clinicians already at the time, was that to rationally 
evaluate and compare individual chemotherapy drugs, one had to take into account the 
particular type of cancer and its developmental stage.27  
Less than a decade later, methotrexate was introduced (known as amethopterin at the time) 
and by early 1960, its combination with 6-mercaptopurine induced sustained remissions in 20 
percent of cases.28 With the addition of cranial irradiation and intrathecal methotrexate to 
previous combination treatments, the concept of being able to cure many children with 
leukemia was solidified.29 The following decades saw rapid improvements in outcome across 
treatment protocols in many countries, mainly through the intensification of therapy, but also 
the addition of new drugs such as asparaginase.26 By the 1980s, the structure of contemporary 
chemotherapy treatment was firmly established; induction of remission, 
intensification/consolidation, and continuation or maintenance therapy. At the same time, 
pediatric oncologists in the Nordic countries, like elsewhere in the world, organized to 
establish common protocols, unifying diagnostics and treatment across the five Nordic 
countries, starting with the NOPHO ALL-92 protocol.22,30 
Beginning with the NOPHO ALL-2008 protocol, cranial irradiation was omitted from the 
treatment of childhood ALL. It also established the standardized use of early minimal 
residual disease (MRD) monitoring and stratification by cytogenetic markers.  
In 2001, Druker et al described the complete hematological response in 53 of 54 chronic 
myeloid leukemia (CML) patients and significant activity in Ph+ blast crisis, all treated with a 
specific BCR-ABL1 inhibitor.31,32 It proved that targeting specific molecular aberrations in 
cancer was not only feasible but potentially transformative for cancer care. While the effect 
of Imatinib and subsequent iterations was not as dramatic in Ph+ ALLs, the addition of 
Imatinib to existing protocols in children with Ph+ ALL has proved beneficial.33 Importantly, 
the successful targeting of the BCR-ABL1 fusion protein has spurred the pursuit to 
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understand the molecular outcome also of other abnormalities in ALL and other cancers, with 
the aim of developing targeted treatments. 
 
Figure 1: Overall survival over consecutive protocols in the Nordic countries and at the 
StJude Children's Research Hospital. A) Consecutive NOPHO ALL (1982-2007) protocols, 
with 2668 children enrolled in the ALL-92 and ALL-2000 protocols. B) Consecutive StJude 
treatment protocols (1962-2007), including a total of 2852 children. Adapted and reprinted 
from Schmiegelow et al30 and Pui and Evans26, with permission from the respective 
publishers. 
1.2.2 Etiology of childhood ALL 
With few exceptions, the etiology of childhood ALL is not known. Ionizing radiation, prior 
chemotherapy or Down Syndrome and other genetic disorders are known to confer an 
increased risk, but together only explain a fraction of cases.19,24 
Assuming a model of cancer development with the sequential acquisition of somatic variants, 
the cumulative risk of developing cancer increases with age and may in large part be 
attributed to the rate of stem cell turnover in the tissue of origin.34,35 It follows that 
manifestations of cancer early in life should be different from those presenting with increased 
frequency towards the end of life. 
Indeed, from a genetic perspective, childhood cancer is by all accounts a special case of 
cancer biology, as evidenced by the consistently low number of protein altering mutations 
detected compared to adult cancers.36 As more studies leverage whole exome or whole 
genome sequencing in the evaluation of somatic mutations in childhood cancer, it is also clear 
that many of them will be carriers of known cancer-predisposing gene variants in their 
germline.37 Furthermore, even in well-characterized subtypes of BCP ALL it is revealed that 
many patients may develop leukemia as a manifestation of a common underlying 
predisposition. This is the case with low hypodiploid ALL (32-39 chromosomes) and 
germline TP53 mutations, the cause of Li Fraumeni syndrome (OMIM#151623).38 
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1.2.2.1 Genetic syndromes and childhood ALL 
Some genetic disorders such as Down syndrome (DS), are not only predisposing to leukemia 
in childhood, but to specific types of leukemia such as acute megakaryoblastic leukemia.39,40 
Indeed, even within ALL patients with DS, they present with high frequencies of very 
specific genetic lesions, particularly JAK-STAT activating JAK2 mutations and CRLF2 
fusions.41,42  
There are a host of other genetic disorders, like Noonan syndrome (OMIM#163950), Fanconi 
anemia (OMIM #227650), Bloom syndrome (OMIM #210900) and ataxia-telangiectasia 
(AT; OMIM #208900) that further highlight the connection between leukemia development 
and predisposing mutations.43 These syndromes are all associated with an increased risk of 
acquiring somatic lesions, either through an overall propensity for chromosomal breakage 
(AT, Fanconi) or more subtly acting gain-of-function sequence mutations (Noonan). This 
highlights common genes and signaling pathways being causative of the germline disorder, as 
well as being the frequent targets of acquired aberrations in ALL and other childhood 
cancers.44 
1.2.2.2 Rare variants and familial predisposition to childhood ALL 
It would not be surprising then, that an appreciable number of individuals that develop cancer 
in childhood, including ALL, are carriers of genetic variants predisposing to cancer 
development.37 Previous epidemiological data in non-syndromic ALL sibships appear to 
support this, revealing subtype concordance between siblings more often than expected which 
suggests shared factors underlying leukemia development.45 
It is only recently, as the scale and scope of genetic analyses has increased, that direct 
evidence has begun to emerge of the presence of individuals and families, not only in the 
context of recognized genetic disorders, that are carriers of variants strongly predisposing to 
childhood ALL.46–49 Interestingly, these studies also indicate that while some associated 
hematological manifestations are evident throughout life, the risk of developing leukemia for 
mutations in for example PAX5 and ETV6, may be limited to childhood and adolescence.46,50 
1.2.2.3 Common variants associated with the development of childhood ALL and response 
to therapy 
For higher frequency alleles in human populations, genome-wide association studies 
(GWAS) have been successful in associating germline genetic variation with the 
predisposition to a whole range of complex and malignant disease.51 Also in childhood ALL, 
GWAS studies have succeeded in highlighting genetic variants in a handful of genes that are 
consistently associated with the risk of developing childhood ALL.52–58 More often than not, 
these variants are found within or in close proximity to known leukemia-associated genes, 
such as IKZF1, CDKN2A and CEBPE. Others like GATA3, a key transcription factor in T-cell 
development, and TP63, a p53-family transcription factor, have been linked to particular 
subtypes of childhood ALL.55,57,59 These variants, even in aggregate, can only account for 
small increases in the risk of developing ALL, and may not be enough to warrant general 
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screening efforts or genetic counseling. However, they may prove useful in highlighting 
biological pathways whose role would not otherwise be recognized as part of leukemia 
development.51 
For the individual patients, common variation in genes involved in the metabolism of anti-
leukemic drugs is already of clinical importance. For example, the metabolism of thiopurines, 
some of the most commonly used drugs in the treatment of ALL, varies significantly between 
patients as a result of common genetic variation in the thiopurine S-methyltransferase 
(TPMT) gene. Carriers of the null gene variant exhibit increased chemosensitivity and a risk 
of excessive treatment related complications at standard doses.60–62 Genotyping or direct 
measurement of TPMT activity is therefore implemented in many protocols today as a means 
of guiding thiopurine concentrations.62 This, and other examples of germline variation 
influencing chemosensitivity, serve to further highlight the importance of detecting them, in 
addition to somatically acquired variation, in advancing the care of children with ALL.63 
Finally, it seems clear that additional genetic variants of low to medium allele frequencies, 
both in genes predisposing to disease as well as those influencing treatment, are likely to be 
discovered as the number of patients analyzed increases the statistical power to do so.51 It is 
not evident whether these variants will ever be of value as direct predictors of childhood 
ALL, or whether their functional impact can be elucidated in detail. Still, the combination of 
rare and common germline variation, including pharmacogenomic information, can be 
successfully be added to established predictors of treatment outcome, such as MRD, to 
introduce toxicity-aware and other rational therapy adjustments.64 
1.2.3 Cytogenetic subtypes in BCP ALL are important predictors of outcome 
In childhood BCP ALL, it is clear that largely non-overlapping subtypes of disease may be 
identified based on the genetic abnormalities they acquire.19,20,65 In the current WHO 
classification, released in 2008, seven subtypes of BCP ALL are recognized: 
t(9;22)(q34;q11.2)/BCR- ABL1, MLL/11q23 translocations, t(12;21)(p13;q22)/ETV6-RUNX1, 
t(1;19)(q23;p13.3)/TCF3-PBX1, t(5;14)(q31;q32)/IGH@-IL3, high hyperdiploidy and 
hypodiploidy.66 
More broadly, subtypes of childhood BCP ALL can be divided into three cytogenetically 
different groups: a) cases with chromosomal translocations, often resulting in activating gene 
fusions, such as cases with t(12;21)/ETV6-RUNX1 or MLL-rearrangements; b) cases with 
non-random loss or gain of whole chromosomes, such as cases of high hyperdiploidy (HeH) 
or hypodiploid ALL; c) other cases with or without detectable cytogenetic aberrations.65  
These subtypes constitute clinically and biologically distinct entities of disease, many of them 
resulting in fusion genes or other associated abnormalities that can directly initiate and/or 
propagate leukemic disease.20 Most common are cases with HeH and the t(12;21)/ETV6-
RUNX1 rearrangement, together accounting for just over half of all cases of BCP ALL (figure 
2). The distribution of is not equal across age groups, however. Within the common age peak 
of ALL, at 2-5 years of age, the proportion of cases with t(12;21)/ETV6-RUNX1 or HeH is 
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very high, while rapidly decreasing with age of diagnosis.65 The t(12;21)/ETV6-RUNX1 is, 
for example, almost completely absent in adult ALL cases, while aberrations such as 
t(9;22)/BCR-ABL1 increase in frequency with age and others, like MLL rearrangements, are 
predominant in very young children.65 
 
 
Figure 2: Recognized subtypes of BCP ALL. The pie chart corresponds to the WHO 
classification of 2008,66 not accounting for abnormalities that were discovered or gained 
recognition after 2004 and the application of genome-wide techniques in childhood ALL. 
Right bar shows the development since, including subtypes defined by copy number profiling 
or gene expression alone. Adapted from Bhojwani et al20 with permission from the publisher. 
Importantly, specific genetic subtypes are often associated to initial treatment response, risk 
of relapse while on therapy and overall survival (Figure 3).63,65 For this reason, many of them 
are routinely screened for at diagnosis using targeted cellular or molecular assays, such as 
fluorescence in situ hybridization (FISH) and reverse-transcriptase PCR (RT-PCR). While 
the precise approach to screening for genetic aberrations differs between laboratories and 
between treatment protocols, almost all genetic laboratories perform some targeted analysis 
in addition to traditional karyotyping by G-banding.65 The NOPHO ALL-2000 protocol 
stipulated the targeted analysis of 11q23/MLL rearrangement, t(1;19)/TCF3-PBX1, 
t(9;22)/BCR-ABL1 and t(12;21)/ETV6-RUNX1.30 The NOPHO ALL-2008 protocol saw the 
addition of several new cytogenetic markers to treatment stratification, requiring, for 
example, the exclusion of dic(9;20) or intrachromosomal amplification of chromosome 21 
(iAMP21) by some method, before allocation to standard-risk treatment.30 
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Figure 3: Kaplan-Meier survival curves, showing the probability of (A) event-free and (B) 
overall survival in 882 BCP ALL cases treated according to the NOPHO ALL-2000 protocol 
by cytogenetic subgroup. Adapted from figure 2 in paper I. 
1.2.4 Childhood BCP ALL in the post-genomic era 
The development of genome-wide microarray based techniques, and later, high-throughput 
sequencing methods, has significantly expanded the range of genetic alterations we know to 
be contributing to the development of ALL.20,67 It was clear from gene expression profiling 
that the recognized cytogenetic subgroups of disease were also associated to molecular 
profiles, and importantly, that entirely new groups of patients could be characterized.68,69 
Genome-wide analyses of copy number alterations in ALL revealed that a number of genes 
crucial to normal B-cell development and differentiation, like PAX5 and IKZF1, were 
recurrently lost or otherwise disrupted in high frequencies in BCP ALL.70–72 These were most 
often secondary events to defined cytogenetic abnormalities, contributing to the development 
and progression of disease. Importantly, some of them, including IKZF1 and CREBBP, have 
been shown associate with high risk disease and poor treatment outcomes.73,74 
From this work, new subtypes of distinct biology and associated clinical outcome have begun 
to emerge (figure 2, sidebar). In particular, the heterozygous deletion of IKZF1, a gene 
encoding the lymphoid transcription factor Ikaros, has consistently been associated with poor 
outcome in BCP ALL.73,75–78 While deletions of IKZF1 are enriched in high-risk and 
cytogenetically non-stratifying ALLs, they can be found across established subtypes of 
disease, and increases the risk of relapse independent of other established risk-factors, such as 
MRD.75,76,78 This highlights the added value of detecting secondary genetic aberrations, also 
within established cytogenetic groups. 
Genome-wide techniques that assay the somatic state epigenetics of childhood ALL have 
added an additional layer of information to our understanding of leukemia development. In 
particular, the genome-wide interrogation of methylation levels at CpG islands, enriched at 
the site of gene promoters, has revealed that different cytogenetic subtypes are highly 
concordant also in their patterns of DNA methylation.79,80 In fact, analysis of diagnostic 
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samples by DNA methylation alone will accurately classify them by subtype, and often 
describe ALLs in which cytogenetics could not be formed or was inconclusive.81 DNA 
methylation can thereby be of value also as a prospective diagnostic tool in ALL. 
1.2.5 The dic(9;20)(p13.2;q11.2) in childhood BCP ALL 
The dic(9;20) was first recognized as a non-random chromosomal abnormality in 1995, with 
case series reporting its recurrence in both adults and children with BCP ALL.82,83 Over the 
next decade, a number of reports brought the total number of cases to 60, and it was now 
evident that the dic(9;20) abnormality occurred preferentially in childhood BCP ALL, 
accounting for over 90 percent of cases.84–90 It occurs most often within the peak age range of 
childhood ALL, between 2-5 years, and has consistently been found to occur with a female 
predominance.85,90 
1.2.5.1 Detection and molecular consequences of the dic(9;20) rearrangement 
The dic(9;20) results in loss of the short arm of chromosome 9 and the long arm of 
chromosome 20, joining 9q and 20p with the respective centromeres in between (figure 4). In 
most cases with dic(9;20), this can render as monosomy 20, and was previously considered a 
good indicator for when to suspect an otherwise subtle dic(9;20)-rearrangement.85 However, 
it would be easy to mistake it for monosomy 20 alone, or in combination with deletion 9p, a 
common event in BCP ALL. Therefore, many cases go undetected using G-banding 
techniques alone.90 
 
Figure 4: Karotype visualized by Giemsa staining (G-banding) in a female with 
46,XX,dic(9;20),+21. A black arrow indicates the subtle abnormality that is dic(9;20). 
Using array comparative genomic hybridization (aCGH) in seven cases with dic(9;20), the 
breakpoints on chr 9 and 20 were shown to cluster within 9p13.2 and 20q11.2, respectively.89 
However, both aCGH and higher resolution SNP array assays revealed that the breakpoints, 
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while clustered, were not identical and likely did not form a consistent fusion gene as a result 
of the dic(9;20) rearrangement.89,91 Still, some dic(9;20)-positive cases do form fusion genes 
involving PAX5 on 9p13.2 and a handful of partners on 20q, as a result of the 
rearrangement.92–94 Other cases are found to harbor PAX5 sequence mutations, or additional 
structural variants.38,71,93 Thus, the suggestion is that disruption of PAX5, through different 
mechanisms, may be the primary functional outcome of the dic(9;20) rearrangement.92 
1.2.5.2 Subtype identity and outcome in dic(9;20)-positive BCP ALL 
To date, over 160 cases of childhood BCP ALL cases with dic(9;20) have been reported, 
including many presented in this thesis. In about half of the cases, dic(9;20) is the only 
chromosomal abnormality.95 While dic(9;20) is detected at comparable frequencies across 
major ALL study groups, with comparable treatment outcomes,20,85,90,96,97 it has only served 
as a risk-stratifying marker in the NOPHO ALL-2008 protocol.30 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to characterize genetic abnormalities of prognostic 
significance in childhood ALL and develop genetic tests for use in the routine laboratory, 
thereby advancing the care of children with leukemia.  
Specifically, our aim was to:  
• Determine the frequency and prognostic impact of the dic(9;20) rearrangement 
 
• Develop better methods of detecting dic(9;20) BCP ALL in a clinical setting 
 
• Understand the molecular consequences of the dic(9;20) rearrangement 
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3 OVERVIEW OF STUDIES 
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4 MATERIALS AND METHODS 
4.1 PATIENTS AND CLINICAL DATA 
4.1.1 Patient cohort, paper I 
 
Figure 5: Schematic overview of cohorts for FISH and survival analysis in paper I, treated 
according to the NOPHO ALL-2000 protocol 
Between January 1, 2001 and December 31, 2006, 1174 infants, children, and adolescents 
<18 years were diagnosed with ALL in the Nordic countries (Denmark, Finland, Iceland, 
Norway and Sweden). Among these, 1033 (88%) were BCP ALL, of which 882 (85%) were 
treated according to the NOPHO ALL 2000 protocol. Risk stratification divided patients into 
standard intensity (SR: WBC ≥ 10 x 109/l, 1-9.9 years, no high risk (HR) features), 
intermediate intensity (IR: WBC > 10 x 109/l, age > 10 years, no HR features) and three HR 
groups (intensive, very intensive, extra intensive). HR features were WBC ≥ 100 x 109/l, 
11q23/MLL rearrangement, t(9;22)(q34;q11), t(1;19)(q23;p13), and hypodiploidy (<45 
chromosomes). The dic(9;20) was not a risk-stratifying aberration in the NOPHO ALL-2000 
protocol.30 Treatment intensity for patients with dic(9;20)-positive ALL was made solely 
based on age, WBC count, the presence of extra-medullary leukemia and morphologic 
response during induction therapy. Karyotyping and targeted analyses was done within the 
NOPHO ALL-2000 protocol for: 11q23/MLL rearrangement, t(1;19)(q23;p13)/TCF3-PBX1, 
t(9;22)(q34;q11)/BCR-ABL1 and t(12;21)(p13;q22)/ETV6-RUNX1. Diagnostic BM smears 
from 533 (52%) of the 1033 BCP ALL patients were successfully analyzed using interphase 
FISH. In the 491 BCP ALLs, which were not analyzed, dic(9;20)-positive cases were 
ascertained using G-banding and metaphase FISH analyses only. 
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4.1.2 Patient cohort, paper IV 
 
Figure 6: Schematic overview of dic(9;20)-positive and other BCP ALLs included in paper 
IV and analyzed by multiple genomic techniques 
In paper IV, we included all 67 cases of dic(9;20) BCP ALL diagnosed between 1996 and 
2013 in the Nordic countries, and that were treated according to the NOPHO ALL-92, ALL-
2000 and ALL-2008 protocols. We analyzed 31 of these cases, from which material was 
available, by one or multiple genomic analyses. The analyzed cases were from all treatment 
protocols; ALL-92 (n=3), ALL-2000 (n=25) and ALL-2008 (n=3). The dic(9;20) 
rearrangement had previously been confirmed in all cases through centrally reviewed 
karyotype data or FISH analysis in paper I, or a combination of DNA-methylation and copy 
number profiling (four cases in paper IV).81 
4.2 CYTOGENETIC ANALYSES 
4.2.1 G-banding and metaphase FISH analysis 
G-banding analyses were performed using standard methods in 15 cytogenetic laboratories in 
the Nordic countries and all abnormal karyotypes were centrally reviewed. In paper I, 
suspected dic(9;20)-positive cases with cells in fixative were analyzed further by metaphase 
FISH analyses to confirm the presence of dic(9;20), using CEP 9 and CEP 20 (Abbott 
Molecular Inc., Des Plaines, IL) and/or WCP 9 and WCP 20 probes (Cytocell Ltd, 
Cambridge, UK),  
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Figure 7: Three-step FISH analysis for the detection of dic(9;20) in paper I 
Bone marrow smears from 533 BCP ALL patients were analyzed in a three-step manner 
(figure 7). The LSI p16 (9p21) FISH probe (Abbott Molecular Inc.), representing a mixture 
of the p16 (official gene symbol CDKN2A) probe labeled with Spectrum Orange and a CEP 9 
probe labeled with Spectrum Green, was used for identifying 9p deletions. Cases with loss of 
CDKN2A, which all dic(9;20)-positive ALL cases have, were subsequently screened, 
according to the manufacturer’s instructions (Abbott Molecular Inc.), with the Vysis 
ToTelvysion probes that are specific for the subtelomeres of 20p and 20q. Cases displaying 
imbalances between the number of signals for 20p and 20q (figure 7, second panel) were 
further analyzed using CEP 9 and CEP 20 probes to confirm the presence of a dicentric 
rearrangement (figure 7, panel 3). 
4.2.2 Design of FISH probe kit 
After mining breakpoint data of all previously published cases of dic(9;20), we designed a set 
of probes that would collectively detect: (i) the unbalanced loss of 20q material, regardless of 
whether one or two normal chromosome 20 homologs are present, and (ii) the co-localization 
of centromeres 9 and 20 (figure 8). Specifically, the probe on 20q is located just distal of the 
most telomeric breakpoints reported in dic(9;20) resulting, if positive, in loss of one signal 
from 20q while still being close enough to ensure the probe’s specificity. Several iterations of 
the co-localization signal was tested on a set of positive and negative controls, altering 
positions and probe size to consistently produce strong and homogeneous signals. BACs 
covering the specified area on 20q11 were sent to Kreatech Diagnostics (Amsterdam, the 
Netherlands) where they were labeled with green and mixed with a centromere-specific probe 
for chromosome 9 (SE9) labeled with blue and a 20p11 probe labeled with red (figure 8). All 
bone marrow slides were prepared according to the manufacturer’s instructions (Kreatech 
Diagnostics) and analyzed using a Zeiss Axioskop 2 (Carl Zeiss, Göttingen, Germany) and 
Smart Capture 3 software (Digital Scientific Ltd, Cambridge, UK).  
 17 
 
Figure 8:Ideogram of chromosomes 9 and 20, illustrating the dic(9;20) FISH probe design. 
Adapted from figure 1 in paper III. 
4.3 STATISTICAL ANALYSES 
In paper I, we calculated the probabilities of EFS (pEFS) and OS (pOS) at five years after 
diagnosis using the Kaplan-Meier method. The different cytogenetic subgroups were 
compared using the log rank test (figure 3). A multivariate analysis was also performed, 
including all cytogenetically defined subgroups and clinical parameters (WBC and age at 
diagnosis). The significance limit for two-sided P-values was set to <0.05 in all tests. Time in 
first remission was defined as time from diagnosis until first event, comprising induction 
failure, relapse, death of disease, death in remission, or second malignant neoplasm. In the 
OS analysis, death of any cause was the endpoint. The median observation time for patients 
in continuous complete first remission (CR1) was 67 months (range 28-108 months). The 
NOPHO leukemia registry is updated annually and follow-up data were extracted from the 
registry on April 1, 2010. The Statistical Package for the Social Sciences (SPSS Inc., 
Chicago, IL) software for Macintosh was used for the statistical analyses.  
In paper IV, we plotted the pEFS, pOS and cumulative incidences of relapse and death, of all 
67 dic(9;20)-positive BCP ALLs using the Kaplan-Meier method in R.98 We compared the 
outcome in NOPHO ALL-92 and ALL-2000 protocols, to the outcome of the ALL-2008 
protocol using the log rank test. Additional statistical methods in genomic analyses were 
implemented as described below. 
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4.4 GENOMIC ANALYSES  
In paper IV, we used multiple genome-wide techniques to profile dic(9;20)-positive BCP 
ALL. We compared them to other subtypes of ALL, both within NOPHO ALL treatment 
protocols and an independent cohort. Figure 6 summarizes the cohorts studied, and figure 9 
the methods used and their corresponding read-out.  
 
Figure 9: Overview of genomic and functional analyses used in paper IV to characterize the 
genetic basis of dic(9;20)-positive BCP ALL 
4.4.1 Detection of copy number alterations 
Copy number alterations (CNA) were detected using Omni 610k (n=1), Omni 2.5M (n=17) 
or 2.5M+Exome (n=7) genotyping arrays (Illumina). Probe intensities were normalized 
against a panel of internal controls to produce log transformed ratios of experimental versus 
 19 
normal reference intensities centered at zero for a diploid sample (log2 ratios, LRR). Quality 
controls included >99% genotype call rate and an LRR standard deviation of <0.15. 
Chromosome X in males was normalized by centering on mean LRR for each chr X position 
(x[sample] - mean[ref]), created from a set of 5 normal germline samples of males (3 CEPH 
males and 2 internal controls of unrelated males). LRR values were segmented using circular 
binary segmentation with default parameters.99 Segmented copy number data was combined 
with probe-level log2 ratios and B-allele frequencies (BAF) to detect allele-specific CNAs 
using the Tumor Aberration Prediction Suite.100 Segments encompassing less than 10 probes 
and smaller than 20kbp were filtered out. Regions of gain, loss and copy neutral loss of 
heterozygosity (CNLOH) were annotated against Ensembl v75, common CNVs from the 
Database of Genomic Variants101 and an in-house database of normal variation from ~4000 
cases evaluated at the Clinical Genetics Service, Karolinska University Hospital. CNAs 
overlapped to more than 90% by a normal CNV were excluded. All annotation, filtering and 
visualization was performed using BEDOPS v2.4.2,102 R v3.1.098 and IGV v2.3.42.103 
In cases lacking SNP array data but with DNA methylation arrays available, intensities from 
the Infinium 450k array (Illumina) were used to map the 9p and 20q breakpoints in IGV, as 
previously described.81 
4.4.2 Whole genome sequencing 
Sequencing libraries were prepared from high molecular weight DNA using Nextera Mate-
Pair Sample Preparation Kit (Illumina Inc, San Diego, CA, USA). DNA sequencing libraries 
with an effective insert size of ~2kb were created for each sample using the Nextera Mate-
Pair sample preparation kit (Illumina). These were then sequenced on an Illumina HiSeq 
2500, 100bp paired-end, to an average raw coverage depth of ~5x. After adapter trimming 
using Trimmomatic and kmer analysis for quality, cleaned reads were aligned to human 
genome reference build GRCh37 using bwa-mem version 0.7.4.104 Mapped reads were 
analyzed for intra- and interchromosomal translocations using a sliding window method 
implemented in FindTranslocations (https://github.com/vezzi/FindTranslocations). In 
addition, putative breakpoints informed by previous patient-specific cytogenetic analysis or 
copy number alterations were directly analyzed for the presence of linking mates using 
IGV.103 
4.4.3 RNA sequencing 
RNA was extracted from diagnostic bone marrow cells after Ficoll gradient separation using 
the AllPrep DNA/RNA or AllPrep DNA/RNA/Protein extraction kit(Qiagen). Sample quality 
and RNA quality was ensured by only including samples with RIN values above 7, measured 
using the RNA Nano Assay 6000 on a Bioanalyzer 2100 (Agilent). Samples were depleted 
for ribosomal RNA using RiboZero (Epicentre) and sequencing libraries were then prepared 
using ScriptSeq v2 (Epicentre), a strand specific protocol. The libraries were sequenced on 
Illumina HiSeq 2000 or 2500 machines with two samples per flowcell lane, 50bp paired-end, 
producing an average of 100 million read pairs per sample. Two additional sequencing 
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libraries from RNA samples of lower quality were prepared using TruSeq RNA Access 
(Illumina). These samples were not included in the gene expression analysis.  
4.4.3.1 Gene expression profiling 
RNA sequence reads were aligned to the human genome reference build GRCh38 (hg38) 
using STAR version 2.4.0j,105 with exon junction support from Ensembl gene annotation 
version 77. Reads overlapping Ensembl features were summarized in each sample using 
featureCounts, as implemented in the subread package version 1.4.6.106,107 Raw read counts 
were normalized by the trimmed mean of M-values normalization method,108 and variance 
normalized using voom.109 Genes with a count of at least 1 per million mapped reads (CPM), 
in at least 2 samples were included for further analysis. Differential gene expression was 
performed by fitting a linear model informed by subgroups, using the R/bioconductor 
package limma.110 Fourteen dic(9;20)-positive cases were contrasted against the combined 
average expression of 32 non-dic(9;20) cases, including HeH, t(12;21)/ETV6-RUNX1, MLL-
rearranged, t(9;22)/BCR-ABL1 and iAMP21. Unsupervised hierarchical clustering, using 
Eucledian distances and complete linkage, was based on the top 1000 (~5%) most variably 
expressed genes across the whole cohort by F test statistic in limma. 
An independent cohort of 118 BCP ALLs, including six dic(9;20), was used to validate the 
dic(9;20) specific expression pattern.38 Gene expression signatures trained to detect BCR-
ABL1-like BCP ALL in previous studies of the DCOG111 and StJude/COG73 groups were 
evaluated in this cohort by unsupervised hierarchical clustering. Affymetrix gene set IDs 
from the original classifiers were converted to EnsemblIDs and used to subset the complete 
set of expressed genes in the cohort. 
Gene set enrichment analysis was performed against Hallmark, C2 and C5 gene sets in 
MSigDB.112 Gene sets including less than 10 genes expressed in this cohort were excluded. 
Where applicable, gene ids or Affymetrix expression array probe sets were converted to 
Ensembl IDs using Biomart.113 In all instances, self-contained gene set testing using rotation 
with was applied, with 10000 permutations, implemented as the mroast function in limma.114 
4.4.3.2 Sequence variant detection 
RNA sequence reads were aligned to the human genome reference GRCh37 (hg19) using 
STAR version 2.4.0j,105 with exon junction support from Ensembl gene annotation version 
75. Duplicate sequence reads were marked using Picard version 1.129 
(http://picard.sourceforge.net) and excluded from further analysis. Using GATK version 3.2-
2,115 sequence reads overlapping exon junctions were split and trimmed to exon boundaries 
and base quality score recalibration applied. Finally, SNV and indel discovery and 
genotyping was performed in individual samples. To reduce likely false positive variant calls, 
hard quality filters were applied; excluding clustered SNPs (>=3 within 35bp), variants with 
high Fisher strand values (FS>30) or low depth-adjusted quality scores (QD<2). To validate 
the overall quality and reliability of the variant calls, we estimated the concordance of 
genotype calls comparing, in each sample, the genotypes from SNP array and RNA-seq 
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genotypes for all positions covered by at least 10 RNA sequence reads. All variants were 
annotated using Ensembl Variant Effect Predictor116 and explored using GEMINI.117 Filtering 
for putative somatic variants were applied as follows: 1) Non-synonymous, stop-gain or 
frameshift variants in coding regions; 2) Supported by at least 10 variant reads, and a 
minimum of 20 total reads; 3) Not in repeat masked region; 4) Previously confirmed as 
somatic in at least two cases reported in COSMIC (http://cancer.sanger.ac.uk/cosmic/), in the 
Pediatric Cancer Genome Project (http://explore.pediatriccancergenomeproject.org) or in 
previous large scale BCP ALL sequencing studies;118,119 5) Visually inspected supporting 
reads in IGV. 
4.4.3.3 Detection of fusion transcripts 
Raw sequence reads in fastq format were analyzed for evidence of fusion transcripts using 
FusionCatcher v0.99.3e.120 Briefly, the algorithm functions by automatically adjusting 
parameters for adapter sequence removal and read trimming according to read length, and by 
mapping sequences to all possible exon-exon junctions leveraging multiple aligners. Putative 
fusions with common mapping reads, indicating a high probability of being false positive 
because of sequence homology, or fusions with both ends mapping to repeat regions were 
excluded. 
4.4.4 DNA methylation analysis 
Previously published DNA methylation levels across 450k CpG sites from twenty 
cytogenetically defined dic(9;20)-positive cases and four characterized by methylation profile 
and CNAs were included in this study.80,81 The twenty cases were previously used as part of a 
training set totaling over 600 childhood ALL samples to build subtype-specific DNA 
methylation classifiers, including a 37-CpG classifier for dic(9;20). Four additional dic(9;20) 
cases were detected by using this classifier to describe a set of cytogenetically uninformative 
cases, and confirmed by the detection of copy number loss of chromosome arms 9p and 
20q.81 
4.4.5 In vitro drug sensitivity assay 
In vitro drug sensitivity data was obtained for all available dic(9;20) and other BCP ALL 
cases for which RNA-seq data was also available. These data were previously published as 
part of a larger NOPHO ALL cohort including 546 BCP ALL samples.121 In short, a 
fluorometric microculture cytotoxicity assay (FMCA) was used to measure the treatment 
response of primary leukemic blasts, obtained at leukemia diagnosis and put in short term 
culture, against a panel of the most commonly used cytotoxic drugs in current leukemia 
treatment protocols. All drugs were tested in triplicate and compared against six non-treated 
wells (controls) and six with medium only (blanks) to calculate a survival index. The FMCA 
thus provides a reliable measure of the overall capability of specific drugs to kill off 
malignant cells, presented here as percent surviving cells.121 
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5 RESULTS AND DISCUSSION 
5.1 FREQUENCY AND CLINICAL CHARACTERISTICS OF DIC(9;20) BCP ALL 
In paper I, we screened 533 cases of childhood BCP ALL diagnosed between 2001-2006 for 
the presence of dic(9;20)(p13.2;q11.2) using interphase FISH (figure 7). During this time 
period, a total of 1174 children were diagnosed with ALL in the Nordic countries, of which 
1033 were BCP ALL. The 491 cases where BM smears were unavailable for FISH analysis 
did not differ significantly in terms of subtype distribution, age, risk grouping and other 
clinical characteristics (not shown). Using a three-step screening approach, deletions of 
9p21.3/CDKN2A were detected in 84/533 (15.7%) of cases, of which 25/84 (29.7%) had 
dic(9;20). In total, the frequency of dic(9;20) was 4.7% (25/533), the third most common 
cytogenetic abnormality after HeH (34%) and t(12;21) (23%) in the cohort. 
The clinical characteristics of dic(9;20)-positive and other BCP ALLs screened by interphase 
FISH were analyzed in paper I and are summarized here in table 1. The median age of 
patients with dic(9;20)-positive BCP ALL was 3.3 years, and the rearrangement was 
associated with slightly higher white blood cell (WBC) counts at diagnosis compared to most 
other subtypes (median 19.2, range 1.6-336). In addition, there was a strong female 
predominance (68%), confirming previous reports of this unusual characteristic for childhood 
ALL.90,97 Importantly, while dic(9;20) was not a risk-stratifying aberration in this protocol, 
the majority of cases (18/25, including one infant) were assigned to non-standard risk 
treatments based on their clinical characteristics alone.  
The dic(9;20) rearrangement was the principal abnormality detected in all but two cases; one 
with t(9;22)/BCR-ABL1 and one with t(12;21)/ETV6-RUNX1. Of the 25 dic(9,20)-positive 
cases detected by interphase FISH, only 11 were also detected at diagnosis by G-banding or 
metaphase FISH. In total, cytogenetic information was available at diagnosis for 20 of the 
dic(9;20)-positive cases, with 15 of them (75%) shown to harbor additional numerical or 
structural changes. Recurrent abnormalities included gains of chr 21 and chr 20, that is two 
normal chr 20 homologues in addition to the dic(9;20). We and others have reported the 
presence of established, primary aberrations in addition to the dic(9;20), also detected in 
paper I in two cases.90,96,97 In paper IV, an additional case harboring both t(12;21)/ETV6-
RUNX1 and dic(9;20) was detected by targeted FISH at diagnosis. Thus, the association with 
both t(9;22)/BCR-ABL1, reported previously in two pediatric cases,88,97 and t(12;21)/ETV6-
RUNX1, reported in two cases in these papers, can be considered recurrent.90 This is 
important to recognize, as the presence of for example BCR-ABL1 dictates a different 
treatment in the current protocols.33 Whether there is an actual difference in outcome for 
cases harboring dic(9;20) alone, compared to its presence in combination with other 
rearrangements, will require the further study of more than the handful of such cases 
currently known.  
In summary, these data show that the frequency of dic(9;20) in BCP ALL is close to 5 
percent, at least twice that detected by G-banding/metaphase analysis alone. This is also 
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consistent with the lower frequency of 1-2.5% reported in all previous studies, all relying on 
chromosome banding analyses alone.85,96,97 While the frequency of dic(9;20)-positive BCP 
ALL was not systematically studied in paper IV, the number of cases with dic(9;20) in the 
NOPHO ALL-2008 protocol were fewer than those reported using the retrospective FISH 
analysis applied in paper I, considering an equivalent number of years and cases (2009-
2013). The total number of dic(9;20)-positive cases during this time period were 21. This is 
comparable to the frequency detected by chromosome banding techniques alone in the ALL-
2000 study (20/1033 in paper I). Assuming the underlying incidence of dic(9;20) did not 
vary between protocols, this suggests that many BCP ALLs with dic(9;20) go undetected also 
in the current protocol iteration. 
5.2 DETECTING THE DIC(9;20) REARRANGEMENT 
From the study in paper 1, it is clear that a significant proportion of cases with dic(9;20) go 
undetected using traditional cytogenetic techniques alone. Of the 25 cases with dic(9;20) 
detected by FISH in paper I, 19 (76%) were scored as having two signals from chromosome 
arm 20p and one from 20q. This pattern is consistent with the presence of the dic(9;20) in 
addition to one normal homologue of chr 20. The other six cases displayed a pattern of three 
signals from 20p and two from 20q, indicating the presence of two normal chr 20 
homologues, in addition to the dic(9;20) rearrangement. In total, we show that almost half of 
dic(9;20) cases harbor an additional chromosome 21 and, in a quarter of cases, two normal 
homologues of chromosome 20 in addition to the dic(9;20). Most dic(9;20)-positive cases 
will therefore go undetected if preferentially screened for in a hypodiploid (<46 chr) cohort or 
focusing solely on cases with monosomy 20.38,85  
For these reasons, we designed a FISH probe kit that could be used to directly screen for the 
dic(9;20) in a clinical setting. In paper III, we combined a set of probes informed by all 
previously reported breakpoints of the dic(9;20) rearrangement, to show the reliable detection 
of dic(9;20) in a single step, suited for clinical diagnostic use (figure 10). We validated the 
probe kit by screening metaphase chromosomes and interphase nuclei from five previously 
identified dic(9;20), including cases both with monosomy 20 and +20. Further, we screened a 
cohort of 50 negative controls, comprising both normal blood and BM smears from diagnosis 
in other childhood ALL and different adult hematological diseases, all of which had 
supporting karyotype data available. In most cases, additional aCGH and/or spectral 
karyotyping had been performed previously and used to support the analysis. No false 
positive cases were detected at a 3% threshold (+3 s.d. from the mean) and metaphases 
showed good specificity and signal (figure 10). Implementing the FISH probe kit for routine 
diagnostics at the Clinical Genetics hospital service, at Karolinska Hospital, two dic(9;20) 
cases were identified prospectively, including one in which the dic(9;20) was present in a 
minor clone at diagnosis and not detected by chromosome banding.  
While the unbalanced nature of the dic(9;20) rearrangement allows its inference from 
genomic profiling, using for example SNP arrays, the dicentric nature of the rearrangement 
cannot be confirmed this way. Further, as we showed using SNP array and WGS analysis in 
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paper IV, the dic(9;20) breakpoints are often located in low-mappability regions on chr 9 and 
chr 20, precluding their detection by WGS or RNA-seq in such cases. In addition, the single-
cell nature of FISH analysis allows the reliable detection of minor clones harboring the 
rearrangement, useful both at diagnosis and during follow-up of treatment. For these reasons, 
we find that the described probe kit is useful in routine clinical diagnostics, either alone or 
complemented with other high-throughput methods. Combining FISH and other methods, we 
expect this will render an accurate diagnosis in more cases with dic(9;20). This is important 
to ensure adequate treatment in protocols using the dic(9;20) as a risk-stratifying marker, like 
the NOPHO ALL-2008 protocol.30 Further, better methods of detection will also improve our 
ability to comprehensively study the clinical implications of dic(9;20) in larger and more 
representative cohorts. 
 
Figure 10: Metaphase chromosomes and interphase nuclei of dic(9;20)-positive cells 
hybridized with a dic(9;20)-targeted probe kit including: centromere 9 (B; blue), 20p (R; red) 
and near centromere 20 (G; green). Positive cells are scored as 1BR, representing the fusion, 
and 1G1R1B, representing normal homologues of chromosome 9 and 20. White arrows 
indicate the dic(9;20) rearrangement in the respective experiments. 
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5.3 TREATMENT OUTCOME 
To study the treatment outcome of dic(9;20)-positive childhood BCP ALL, in paper I we 
analyzed the survival of 882 children uniformly treated according to the NOPHO ALL-2000 
protocol. Combining the dic(9;20) cases detected by FISH with additional cases detected at 
diagnosis by G-banding or metaphase FISH alone, there were 29 dic(9;20)-positive BCP 
ALLs treated according to the ALL-2000 protocol. Of these, seven cases suffered relapses 
(24%): four in the BM (7-33 months after diagnosis) and three with isolated CNS relapses 
(22-29 months after diagnosis). All cases with BM relapses were classified as HR at initial 
risk stratification, while the CNS relapses were SR or IR. Further, the proportion of CNS 
relapses in dic(9;20) was higher than in the cohort as a whole,  3/7 (43%) in dic(9;20) versus 
19/128 in other BCP ALLs (15%), but did not reach statistical significance (chi square 3.81; 
p=0.0506). Two additional events occured in cases with dic(9;20); one infection-related death 
in CR1 (HR treatment) and one patient that developed a non-Hodgkin lymphoma 30 months 
after diagnosis (SR treatment).  
In total, the nine primary events in dic(9;20) cases rendered a pEFS of 0.69 at 5 years after 
diagnosis. Analyzed by paired univariate analysis, this was significantly worse than for cases 
with t(12;21) (pEFS=0.87; p=0.002) and with HeH (pEFS=0.82; p=0.04) (figure 3A). By Cox 
multivariate analysis, accounting for cytogenetic subgroups, WBC, age and with dic(9;20)-
positive cases as reference, only t(12;21)-positivity associated in a significantly superior 
outcome. In the whole cohort of 882 BCP ALLs, WBC count at diagnosis was the most 
powerful predictor of EFS. 
Of the nine dic(9;20) cases with primary events, there were four deaths (13.7%) - three 
related to disease, and one in complete remission. The overall survival at 5 years after 
diagnosis was 0.85 (figure 3B) - worse than for t(12;21) cases in univariate analysis 
(pOS=0.97; p=0.002). Again in multivariate analysis, as described, WBC and age at 
diagnosis were found to be the strongest predictors of OS in the cohort as a whole (p<0.01). 
Of the cytogenetic abnormalities, only t(12;21) was significantly associated with OS 
(p=0.035).  
Together, these data show that a significant proportion of dic(9;20)-positive BCP ALL cases 
relapsed when treated on the NOHO ALL-2000 protocol, resulting in a lower EFS compared 
to the most common, standard-risk aberrations. However, many dic(9;20) appeared to 
respond well to second-line treatment with an OFS that was only worse compared to cases 
with t(12;21). Comparable survival data in dic(9;20) in other treatment protocols are only 
available from smaller patient cohorts, often treated across protocol iterations96,97 In an ALL-
BFM study including 19 dic(9;20)-positive cases, there were fewer relapses (16%) and 
somewhat better outcome measures than those described in paper I (5 year EFS rate 75%; 5 
year OS rate 94%).97 However, also in this study there were several cases with CNS 
involvement at diagnosis and CNS relapses. In a smaller number of dic(9;20) BCP ALLs 
treated on the UKALL97/99 protocols, again 5 year pEFS and pOS were relatively favorable 
at 77% and 92%, respectively.96  
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In paper IV, we extended this analysis to include an additional 19 dic(9;20)-cases from the 
NOPHO ALL-2008 protocol. Here, we compared the clinical outcome of dic(9;20)-positive 
cases specifically, treated according to the ALL-92 or ALL-2000 protocol (without dic(9;20) 
stratification) to those on the ALL-2008 protocol (with dic(9;20) stratified to the IR treatment 
arm). While the number of dic(9;20) cases enrolled in the NOPHO ALL-2008 protocol were 
too few to allow statistical certainty, a single primary event was reported among the patients 
on the ALL-2008 protocol (a death in complete remission). Thus, there was a trend towards 
improved survival in the new protocol that requires further study. Considering that most 
dic(9;20)-positive cases were already stratified to non-standard risk treatment in the ALL-
2000 protocol (table 1), based on clinical characteristics alone, the reason for this apparent 
difference in outcome is not immediately clear. 
 
Figure 11: Probability of disease-free (left) and overall (right) survival of dic(9;20)-positive 
cases treated according to the NOPHO ALL-92 and 2000 (grey) compared to the ALL-2008 
(blue) protocols, plotted as Kaplan-Meier curves and compared using the log-rank test. 
There was a single death among the ALL-2008 cases that occurred during first complete 
remission. Censored cases are marked with vertical bars and shaded areas for each protocol 
represent 95% confidence intervals. 
5.4 BREAKPOINT MAPPING AND FUSION GENE DETECTION 
To characterize the breakpoints in dic(9;20) in detail, we analyzed DNA from diagnostic BM 
samples using SNP arrays - first in paper II, then extended and with higher resolution in 
paper IV. As previously shown, dic(9;20) breakpoints are heterogeneous both on 9p and 
20q.89,92,93 Here, most breakpoints on 9p were found to occur within or directly upstream of 
PAX5, with a second significant cluster in low-mappability and repeat regions near 
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centromere 9. The breakpoints on 20q were found to display more variability with no 
consistent correlation to the breakpoints on 9p, again in line with previous results.93 In total, 
the breakpoints could be ascertained in 30 cases. In twelve of these, the break on 9p was 
located within PAX5 - five of which also had intragenic NOL4L breaks at 20q11.2. By using 
RNA-sequencing and WGS in paper IV, we could detect the in-frame fusion gene PAX5-
NOL4L (previously C20orf112) in 4 of 16 samples (figure 12). Two cases carried an identical 
fusion involving PAX5 exon 5 and NOL4L exon 8, a configuration that has been reported 
previously.92 All four of the detected fusions were predicted to be in-frame and retain the 
DNA binding domain of PAX5. Together, these data show that PAX5-NOL4L is a recurrent 
fusion gene in dic(9;20), as detected by multiple techniques, but that PAX5 fusions cannot 
account for all dic(9;20)-positive cases. Further, we detect a number of other cases with 
breakpoints within PAX5 and where the corresponding breakpoints on chr 20 are in non-
recurrent and intergenic region, questioning the formation a fusion gene even when PAX5 is 
directly involved. 
The PAX5 gene, encoding a transcription factor central to B-cell development and lineage 
identity,122 is the most frequently altered gene in childhood BCP ALL.71 Fusion genes 
involving PAX5 have been reported with a variety of 3' partners, both in other dic(9;20)-
positive cases92,94 and childhood ALL in general.123–125 Some of the fusions are predicted to 
disrupt normal PAX5 protein function, either through haploinsufficiency or by dominant-
negative suppression of wt PAX5 protein.126 However, it is clear that the wide variety of 3' 
partners also results in considerable heterogeneity regarding the precise functional outcome 
of PAX5 fusion genes.123 For the PAX5-NOL4L fusion specifically, previous protein studies 
have shown that it is likely to result in suppression of wt PAX5 function, binding with up to 
10-fold higher affinity to PAX5-target sites.126 Together with other structural variants and 
mutations commonly reported in PAX5, it is therefore thought that the dic(9;20) 
rearrangement ultimate serves to disrupt PAX5.92 To analyze this in our cohort, we 
investigated a well-characterized set of PAX5 target genes for evidence of differential 
expression in dic(9;20)-positive cases compared to other BCP ALLs. Gene set enrichment 
analysis of known PAX5 targets did not show any significant transcriptional deregulation of 
downstream genes, suggesting other aberrations may be important in cases with dic(9;20). 
To characterize further cases with unclear breakpoints or suspected cryptic rearrangements, 
we applied low-coverage mate-pair sequencing in four cases. As expected, we could confirm 
the PAX5-NOL4L in a case with corresponding breakpoints on the SNP array and RNA-
sequencing data supporting the same fusion. In another case, SNP array analysis had revealed 
a deletion of 9p extending beyond 9p13.2 and into 9q. Despite this, WGS revealed the 
presence of a PAX5-NOL4L fusion also in this case (figure 12, case KSALL4). It was part of 
a complex rearrangement, duplicated at the breakpoint sites at 9p13.2 and with links between 
each of 9p, 9q and 20q – all confirmed by Sanger sequencing.  
In another two cases, one analyzed by WGS, there was evidence of a small, retained region 
within the extended deletion of 20q. In both cases, the retained region included only PTPRT, 
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a protein tyrosine phosphatase gene. Using WGS followed by Sanger sequencing, we found 
this ~1.4Mb fragment to be inserted between the 9p and 20q arms in the dic(9;20) 
rearrangement. The effect of this is unclear, however, as the PTPRT gene was not expressed 
in any of the cases subjected to RNA-sequencing in paper IV. 
 
Figure 12: PAX5-NOL4L is a recurrent fusion gene in dic(9;20)-positive BCP ALL. Protein 
models of PAX5 (dark blue) and NOL4L (yellow) are shown in four cases, as detected by 
RNA-seq or WGS in paper IV and adapted from figure 2. The respective breakpoints are 
marked with vertical dotted lines, labeled with the corresponding exons involved in the 
fusion. 
5.5 SECONDARY GENETIC ABERRATIONS ASSOCIATED WITH DIC(9;20) 
In papers II and IV, we wanted to extend the spectrum of known genetic aberrations 
associated with the dic(9;20). Most strikingly, homozygous deletions of the tumor suppressor 
gene CDKN2A were present in all but one of 25 dic(9;20)-positive cases analyzed by SNP 
array (figure 13). Gene expression data also confirmed a significant suppression of CDKN2A 
expression in dic(9;20) as compared to other BCP ALLs (-5.21 log2 FC; adj p < 0.001). This 
locus encodes two independent tumor suppressors, P14ARF and P16INK4 from overlapping 
reading frames, and at least one copy of the gene is deleted in up to 35% of BCP ALL 
cases.71,127 Its association with treatment outcome has rendered conflicting results, possibly 
owing to the varying frequency of CDKN2A deletions between different subgroups.127 
In paper II, we showed that these CDKN2A deletions are present on the non-rearranged 
homologue of chromosome 9, one allele always lost as a result of the dic(9;20) 
rearrangement. The deletions were almost all below the resolution of FISH and their 
breakpoints appeared clustered. Extended to a larger number of cases in paper IV, the same 
clustering was evident. In 20 of 24 cases with homozygous deletion of CDKN2A, the lower 
end (centromeric) of the deletions all clustered tightly within CDKN2B (figure13). This is 
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suggestive of a common underlying mechanism, such as the ectopic activity of the RAG1/2 
endonuclease complex.119,128 In one case, we could map the exact breakpoints of the deletion 
using WGS (figure 13, bottom panel). This revealed the presence of cryptic recombination 
signal sequences, required for RAG1 guiding, directly within the breakpoints of the deletion. 
The location was off by just a few base pairs from similar deletions in two previously 
published ETV6-RUNX1 cases.119 In summary, homozygous deletions of CDKN2A deletions 
are present in almost all dic(9;20)-positive cases, more often than in other subgroups, and me 
be caused by aberrant RAG-mediated recombination. 
 
Figure 13: Homozygous deletions of CDKN2A occur in almost all dic(9;20)-positive BCP 
ALLs. Shown are 25 cases included in paper II and paper IV, with copy number states as 
segmented logR ratios (LRR) at 9p21.3. Light blue indicates heterozygous deletions, dark 
blue homozygous deletions. Clinical events are highlighted in the left column. Bottom panel 
shows case KSALL4, analyzed by WGS in paper IV, with read sequence pairs spanning the 
break in concordance with SNP array data. 
In paper IV, we also detected an unexpectedly high frequency of heterozygous deletions of 
IKZF1 (9/25; 36%) – a known predictor of poor outcomes across subgroups in childhood 
BCP ALL.73,75–78 We could not detect a difference in IKZF1 expression as a result, consistent 
with a change in relative isoform distribution (increase in Ik6 levels) rather than overall 
expression.73 In this dic(9;20) cohort, most primary events (4/6 total, including 5 relapses) 
occurred in cases with a deletion of IKZF1 but was not statistically significant (chi-square 
3.22; p=0.072). Considering the known prognostic effect of IKZF1 deletions, it will be 
important to study this further in dic(9;20)-positive cases and understand to what extent they 
account for the risk of relapse in this subgroup. 
Finally, we used RNA-sequence data to look for single-nucleotide variants of putative 
somatic origin in cases with dic(9;20). Five of 14 cases (35%) were shown to have mutations 
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in Ras/MAPK-pathway genes, including KRAS, NRAS and PTPN11. This is a comparable 
frequency to that of other BCP ALL subtypes,38,118,129 but it remains to be studied whether 
these represent subclonal events or important drivers in dic(9;20)-positive leukemia. 
5.6 INTEGRATED GENOMIC PROFILING OF DIC(9;20)-POSITIVE CELLS 
In paper IV, we also studied the overall gene expression and DNA methylation profiles of 
dic(9;20)-positive BCP ALL compared to other subgroups. Comparing RNA-seq data in 14 
dic(9;20) cases against a set of 32 other BCP ALLs, including most major subtypes, 
hierarchical clustering revealed a distinct expression pattern in cases with dic(9;20). This was 
also true when limiting the analysis to non-coding genes alone, suggesting that the 
differentiating features of dic(9;20) are not limited to protein-coding genes. 
Some of the most differentially expressed genes in dic(9;20)-positive cases were CDKN2A, 
JAK2 and others affected by detected copy number alterations (homozygous deletion and loss 
of 9p, respectively). Other genes with significant changes in expression levels included lower 
levels of DAPK1, SMAD1 and increased expression of KCNQ5. Most of these findings were 
validated in an independent cohort of BCP ALLs, including six dic(9;20), that had gene 
expression data together with cytogenetic data available for analysis.38 Further analysis of the 
gene expression data revealed four key gene sets (MSigDB, Hallmark set) that showed 
significant directional enrichment in dic(9;20)-positive cases, most significantly positive 
enrichment for genes involved in TNFalpha signaling via NFkB and apoptosis.  
To understand the overall pattern of gene expression in dic(9;20)-positive BCP ALL, we 
integrated the gene expression data with DNA methylation data from the same cases.80 Most 
of the differentially methylated CpGs in dic(9;20), as reported previously,80 were annotated to 
genes not expressed in this cohort. However, comparing the genes included in a DNA 
methylation-based dic(9;20), 7 of 19 genes (37 CpG sites in total) also revealed significant 
differential expression in the RNA-seq data. Both DAPK1 and SMAD1 showed increased 
levels of promoter hypermethylation in dic(9;20) – thus explaining the lower gene expression 
in the absence of structural or other sequence-level aberrations (figure 14A-B).  
Death associated protein kinase 1 (DAPK1) is a key pro-apoptotic protein and regulator of 
autophagy, often hypermethylated in cancer and in particular in chronic lymphocytic 
leukemia.130 SMAD1 is involved in the TGFbeta and BMP signaling cascade, and an 
important regulator of transcription. Interestingly, both DAPK1 and SMAD1 were among the 
top downregulated genes in mice with short latency to leukemia development, when 
engrafted with primary cells from childhood BCP ALLs.131 Evaluating these sets of genes in 
dic(9;20)-positive cases showed a significant correlation for genes both up- and 
downregulated in the short-latency leukemia model. Taken together, these results reveal that 
somatic state epigenetic changes in dic(9;20)-positive BCP ALL confer significant changes to 
the expression of genes involved in cell survival signaling and regulation of programmed cell 
death. Further, the deregulation of these genes may be part of an expression profile, 
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constitutive to the leukemic cells, that is conductive to initiation and/or progression of 
disease. 
Overexpression of DAPK1 was previously reported to predict increased glucocorticoid 
resistance in childhood BCP ALL.132 Therefore, we investigated whether lower levels of 
DAPK1 were correlated to differential sensitivity to a panel of anti-leukemic drugs. 
Comparing FMCA in vitro sensitivity data and gene expression in dic(9;20)-positive cases 
revealed an increased sensitivity to glucocorticoids with lower levels of DAPK1 (figure 14C). 
Together with the data from the xenograft models, this suggests that the effect of DAPK1 de-
repression, using demethylating compounds for example, may render conflicting results in 
the context of existing chemotherapy regimens in childhood ALL – possibly removing strong 
growth advantages, but at the same time making cells less sensitive to common anti-leukemic 
agents. 
 
Figure 14: DAPK1 is downregulated through promoter hypermethylation in dic(9;20)-
positive BCP ALL and lower DAPK1 expression correlates to increased glucocorticoid 
sensitivity. A) CpG methylation levels across the DAPK1 gene model, with a heatmap of 
unsupervised hierarchical clustering on rows (blue – low methylation, red – high 
methylation). Below is the Spearman’s rank correlation for each CpG to overall DAPK1 
expression, with confidence intervals as vertical bars and yellow marking significantly 
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correlated CpG sites. DAPK1 expression data in individual samples , were available, shown 
in a single column heatmap to the right. B) Correlation of DAPK1 expression and DNA 
methylation at one CpG site, highlighted with a thick black line in panel A. LOESS curves are 
fitted and individual samples colored by subgroup. Spearman rank correlation (-0.851, 
p<0.001) is top right. C) DAPK1 expression compared to in vitro drug sensitivity, measured 
as percent surviving cells, in the top four drugs in the analysis. 
In summary, in paper IV, we have presented an integrated analysis of structural and single 
nucleotide changes, combined with DNA methylation and gene expression profiling in 
dic(9;20)-positive BCP ALL. Together, these data extend the spectrum of known genetic 
aberrations in cases with dic(9;20) and highlight several key genes deregulated through 
epigenetic mechanisms – some of them conferring differential sensitivity to existing anti-
leukemic agents. 
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6 CONCLUSIONS 
The main conclusions of the studies presented in this thesis are:  
• The dic(9;20)(p13.2;q11.2) chromosomal abnormality is more common than 
previously appreciated in childhood B-cell precursor ALL 
 
• The dic(9;20) is often associated with non-standard risk clinical features at diagnosis, 
an increased risk of relapse and worse event-free survival compared to the most 
common BCP ALL subtypes 
 
• The subtle nature of the rearrangement requires using a targeted FISH analysis for the 
reliable detection of all dic(9;20) cases in a clinical setting 
 
• Fusion genes involving PAX5 are recurrent in dic(9;20), but cannot account for the 
subtype or their overall expression profile 
 
• The full spectrum of genetic abnormalities in dic(9;20)-positive cases include 
recurrent activating mutations in the Ras/MAPK pathway, near obligate loss of tumor 
supressor CDKN2A by ectopic RAG endonuclease activity, and an enrichment of 
IKZF1 deletions 
 
• Genes controlling cell survival signaling and programmed cell death, including 
DAPK1 and UAP1, are epigenetically downregulated in dic(9;20) – influencing the 
sensitivity to existing anti-leukemic agents and revealing rational targets of possible 
new therapies 
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7 FUTURE PERSPECTIVES 
New molecularly targeted therapies and the emerging field of cancer immunotherapy promise 
to transform the way we treat and care for children with ALL, much in the way 
chemotherapeutic drugs first did in the previous century. Already today, an expanded 
portfolio of kinase inhibitors are proving useful in certain subtypes of ALL, and early data on 
chimeric antigen receptor T-cell engineering (CAR-T) in treating ALL are so promising that 
they look set to become the next landmark in childhood ALL therapy, possibly replacing 
stem-cell transplantations in those with the worst prognosis.  
Resolving additional genetic aberrations, also in standard-risk ALLs, and how they relate to 
overall changes in somatic state epigenetic conformation, gene and protein expression, will 
continue in the years to come and render additional insights. With the techniques already 
available to us - and foreseeable further advancements in reading and editing the genome - 
these developments are squarely within a set of questions we already know to ask and will 
soon answer. 
Together, an increased understanding of the genetic basis of disease, coupled with entirely 
new avenues of therapy, will provide never before seen opportunities to treat childhood ALL. 
The difference from previous advances is, of course, that childhood ALL today is a highly 
curable disease, far from the futile medical problem it once symbolized. Therefore, while 
emerging therapies have already started finding uses in high-risk cases, it is not immediately 
clear how to apply them for the benefit of the majority of children with ALL to afford a 
reduction in the intensity of chemotherapy treatment. 
Our main challenge, as researchers and treating physicians, may in the end lie not only in 
finding all the different ways in which we can kill off a leukemic cell – but how to test and 
implement the best ones without jeopardizing previous gains; and to do so in an overall 
population of childhood ALLs of predominantly low-risk disease.  
In parallel, we are tasked to use what is already known and available to us today, to increase 
access to modern diagnostics and adequate care for the 80 percent of children diagnosed with 
cancer that are treated outside contemporary protocols and care facilities. This highlights the 
fact that, globally, there is already today large outcome gains to be made in the care of 
children with cancer. In terms of diagnostics, new low-cost and widely applicable solutions 
for the analysis of genetic abnormalities are sure to be ahead of us, as the fields of molecular 
genetics, engineering and computer science intersect more often. 
For all these reasons, it should be evident that a cure for all children with ALL is within 
reach, but that it will come only from a detailed understanding of the genetics of the disease, 
the determinants of therapy response, and the careful consideration of how to best leverage 
this clinically. 
 
 36 
8 ACKNOWLEDGEMENTS 
I am indebted to our patients, their families and treating physicians, without whom this 
research would not have been possible.  
My main supervisor, Ann Nordgren, for her unwavering trust and support, leaving me to 
explore any and all ideas, and for bringing an unparalleled excitement to what we do, in every 
meeting, every single encounter, over the last four years. My co-supervisors, Magnus 
Nordenskjöld, Gisela Barbany and Erik Forestier for taking me on as a student. For 
always being generous with their time and patience through the course of this work. 
The rest of the leukemia genetics working group: Ingegerd Ivanov Öfverholm, Anh-Nhi 
Tran, Fulya Taylan; for sharing all the gritty work in planning, executing and interpreting 
much of the work presented here. 
To all the researchers and physicians that contributed to and co-authored the studies included 
in this thesis, proving that the most interesting and rewarding science is done in collaboration. 
In particular Jessica Nordlund, who has been instrumental to much of work presented in this 
thesis. Ann-Christine Syvänen, Gudmar Lönnerholm, Yanara Marincevic-Zuniga for 
successful collaborations. To Dan Grandér and Katja Pokrovskaja, for the collaboration 
and their time and many discussions.  
To pediatric oncologists across the Nordic countries, and associated scientists within NOPHO 
and the NOPHO ALL Biology Working group. In particular Mats Heyman, Arja Harila-
Saari, Kjeld Schmiegelow, Olli Lohi who have all been the very best representatives of 
physician scientists; for being passionate and unrelenting advocates of inclusive 
collaborations with the patients at heart, and for putting trust in me and other young scientists 
to help shape the pediatric cancer research of tomorrow.  
The Clinical Genetics research group at CMM, past and present. In particular Bianca Tesi 
who, more than anyone, has had to listen to my incessant talking during the last few years; 
and for becoming data-literate together. Tobias, Alexandra, Wolfgang, Daniel, Anna, 
Marie, Johanna, Anders, Malin, Ellika, Sigrid, Nina, Josefine, Maria, Miriam, Samina, 
Alice, Alisa, Paris.  
All clinicians and laboratory staff at the Clinical Genetics hospital service.  
All the incredibly patient and helpful administrative personnel at the Department of 
Molecular Medicine and Surgery. 
I am also grateful for the financial support of Karolinska Institutet, Stockholms läns 
landsting, Barncancerfonden, and Mery Bevé foundation. For funding this work and allowing 
me to travel and learn science around the world during these years. 
My family. 
My love. 
 37 
9 REFERENCES 
1. Lander, E. S. et al. Initial sequencing and analysis of the human genome. 
Nature 409, 860–921 (2001). 
2. Venter, J. C. et al. The Sequence of the Human Genome. Science 291, 1304–
1351 (2001). 
3. Lander, E. S. Initial impact of the sequencing of the human genome. Nature 
470, 187–197 (2011). 
4. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for 
transcriptomics. Nat. Rev. Genet. 10, 57–63 (2009). 
5. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome — 
biological and translational implications. Nat. Rev. Cancer 11, 726–734 (2011). 
6. Yang, Y. et al. Clinical Whole-Exome Sequencing for the Diagnosis of 
Mendelian Disorders. N. Engl. J. Med. 369, 1502–1511 (2013). 
7. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 
458, 719–724 (2009). 
8. Boycott, K. M., Vanstone, M. R., Bulman, D. E. & MacKenzie, A. E. Rare-
disease genetics in the era of next-generation sequencing: discovery to translation. Nat. Rev. 
Genet. advance online publication, (2013). 
9. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. 
Cell 144, 646–674 (2011). 
10. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 
(2012). 
11. Stephens, P. J. et al. Massive Genomic Rearrangement Acquired in a Single 
Catastrophic Event during Cancer Development. Cell 144, 27–40 (2011). 
12. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer 
genomes through second-generation sequencing. Nat Rev Genet 11, 685–696 (2010). 
13. Fredriksson, N. J., Ny, L., Nilsson, J. A. & Larsson, E. Systematic analysis of 
noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat. 
Genet. 46, 1258–1263 (2014). 
14. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. 
Genet. 45, 1134–1140 (2013). 
15. Kandoth, C. et al. Mutational landscape and significance across 12 major 
 38 
cancer types. Nature 502, 333–339 (2013). 
16. Landau, D. A., Carter, S. L., Getz, G. & Wu, C. J. Clonal evolution in 
hematologic malignancies and therapeutic implications. Leukemia (2013). 
doi:10.1038/leu.2013.248 
17. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed 
by whole-genome sequencing. Nature advance online publication, (2012). 
18. Gerlinger, M. et al. Intratumor Heterogeneity and Branched Evolution 
Revealed by Multiregion Sequencing. N. Engl. J. Med. 366, 883–892 (2012). 
19. Pui, C.-H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. The 
Lancet 371, 1030–1043 (2008). 
20. Bhojwani, D., Yang, J. J. & Pui, C.-H. Biology of Childhood Acute 
Lymphoblastic Leukemia. Pediatr. Clin. North Am. 62, 47–60 (2015). 
21. Howard, S. C. et al. Childhood cancer epidemiology in low-income countries. 
Cancer 112, 461–472 (2008). 
22. Gustafsson, G. et al. Improving outcome through two decades in childhood 
ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS 
irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14, 
2267–75 (2000). 
23. Pui, C.-H. Genomic and pharmacogenetic studies of childhood acute 
lymphoblastic leukemia. Front. Med. 1–9 (2014). doi:10.1007/s11684-015-0381-3 
24. Belson, M., Kingsley, B. & Holmes, A. Risk Factors for Acute Leukemia in 
Children: A Review. Environ. Health Perspect. 115, 138–145 (2007). 
25. Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F. & Wolff, J. A. 
Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 
4-Aminopteroyl-Glutamic Acid (Aminopterin). N. Engl. J. Med. 238, 787–793 (1948). 
26. Pui, C.-H. & Evans, W. E. A 50-Year Journey to Cure Childhood Acute 
Lymphoblastic Leukemia. Semin. Hematol. 50, 185–196 (2013). 
27. Farber, S. Advances in cancer research. (Academic Press, 1956). 
28. Frei, E. et al. Studies of Sequential and Combination Antimetabolite Therapy in 
Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood 18, 431–454 (1961). 
29. Aur, R. J. A. et al. Central Nervous System Therapy and Combination 
Chemotherapy of Childhood Lymphocytic Leukemia. Blood 37, 272–281 (1971). 
30. Schmiegelow, K. et al. Long-term results of NOPHO ALL-92 and ALL-2000 
 39 
studies of childhood acute lymphoblastic leukemia. Leukemia 24, 345–54 (2010). 
31. Druker, B. J. et al. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine 
Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia 
with the Philadelphia Chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). 
32. Druker, B. J. et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL 
Tyrosine Kinase in Chronic Myeloid Leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). 
33. Biondi, A. et al. Imatinib after induction for treatment of children and 
adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia 
(EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 13, 936–945 (2012). 
34. Jacobs, K. B. et al. Detectable clonal mosaicism and its relationship to aging 
and cancer. Nat. Genet. 44, 651–658 (2012). 
35. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be 
explained by the number of stem cell divisions. Science 347, 78–81 (2015). 
36. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for 
new cancer-associated genes. Nature 499, 214–218 (2013). 
37. Plon, S. E. et al. Abstract 11: Evaluating cancer susceptibility mutations and 
incidental findings from whole exome sequencing of sequentially diagnosed pediatric solid 
and brain tumor patients: Early results of the BASIC3 study. Cancer Res. 74, 11–11 (2014). 
38. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic 
leukemia. Nat. Genet. (2013). doi:10.1038/ng.2532 
39. Buitenkamp, T. D. et al. Acute lymphoblastic leukemia in children with Down 
syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123, 70–77 
(2014). 
40. Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid 
tumours in individuals with Down’s syndrome. The Lancet 355, 165–169 (2000). 
41. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly 
heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated 
JAK2: a report from the International BFM Study Group. Blood 115, 1006–1017 (2010). 
42. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias 
associated with Down’s syndrome. The Lancet 372, 1484–1492 (2008). 
43. Seif, A. E. Pediatric leukemia predisposition syndromes: clues to understanding 
leukemogenesis. Cancer Genet. 204, 227–244 (2011). 
44. Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic 
leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34, 148–150 
 40 
(2003). 
45. Schmiegelow, K. et al. High concordance of subtypes of childhood acute 
lymphoblastic leukemia within families: lessons from sibships with multiple cases of 
leukemia. Leukemia 26, 675–681 (2012). 
46. Zhang, M. Y. et al. Germline ETV6 mutations in familial thrombocytopenia 
and hematologic malignancy. Nat. Genet. 47, 180–185 (2015). 
47. Noetzli, L. et al. Germline mutations in ETV6 are associated with 
thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. 
Genet. advance online publication, (2015). 
48. Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline 
transmission of PAX5 c.547G>A. Leukemia (2013). doi:10.1038/leu.2013.363 
49. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to 
pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226–1231 (2013). 
50. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to 
pre-B cell acute lymphoblastic leukemia. Nat. Genet. advance online publication, (2013). 
51. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five Years of 
GWAS Discovery. Am. J. Hum. Genet. 90, 7–24 (2012). 
52. Papaemmanuil, E. et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated 
with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006–1010 (2009). 
53. Treviño, L. R. et al. Germline genomic variants associated with childhood acute 
lymphoblastic leukemia. Nat. Genet. 41, 1001–1005 (2009). 
54. Sherborne, A. L. et al. Variation in CDKN2A at 9p21.3 influences childhood 
acute lymphoblastic leukemia risk. Nat Genet 42, 492–494 (2010). 
55. Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like 
childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. (2013). 
doi:10.1038/ng.2803 
56. Xu, H. et al. Novel Susceptibility Variants at 10p12.31-12.2 for Childhood 
Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. J. Natl. Cancer Inst. 
(2013). doi:10.1093/jnci/djt042 
57. Migliorini, G. et al. Variation at 10p12.2 and 10p14 influences risk of 
childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013). 
doi:10.1182/blood-2013-03-491316 
58. Rudant, J. et al. ARID5B, IKZF1 and Non-Genetic Factors in the Etiology of 
Childhood Acute Lymphoblastic Leukemia: The ESCALE Study. PLoS ONE 10, e0121348 
 41 
(2015). 
59. Ellinghaus, E. et al. Identification of germline susceptibility loci in ETV6-
RUNX1-rearranged childhood acute lymphoblastic. Leukemia 26, 902–909 (2012). 
60. Krynetski, E. Y. et al. A single point mutation leading to loss of catalytic 
activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. 92, 949–953 (1995). 
61. Relling, M. V. et al. Mercaptopurine Therapy Intolerance and Heterozygosity at 
the Thiopurine S-Methyltransferase Gene Locus. J. Natl. Cancer Inst. 91, 2001–2008 (1999). 
62. Schmiegelow, K. et al. Thiopurine methyltransferase activity is related to the 
risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 
study. Leukemia 23, 557–564 (2008). 
63. Pui, C.-H. & Evans, W. E. Treatment of Acute Lymphoblastic Leukemia. N 
Engl J Med 354, 166–178 (2006). 
64. Wesołowska-Andersen, A. et al. Genomic profiling of thousands of candidate 
polymorphisms predicts risk of relapse in 778 Danish and German childhood acute 
lymphoblastic leukemia patients. Leukemia 29, 297–303 (2015). 
65. Moorman, A. V. The clinical relevance of chromosomal and genomic 
abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 26, 123–135 
(2012). 
66. WHO classification of tumours of haematopoietic and lymphoid tissues: [... 
reflects the views of a working group that convened for an Editorial and Consensus 
Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 
27, 2007]. (Internat. Agency for Research on Cancer, 2008). 
67. Harrison, C. J. Targeting signaling pathways in acute lymphoblastic leukemia: 
new insights. ASH Educ. Program Book 2013, 118–125 (2013). 
68. Yeoh, E.-J. et al. Classification, subtype discovery, and prediction of outcome 
in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133–
143 (2002). 
69. Ross, M. E. et al. Classification of pediatric acute lymphoblastic leukemia by 
gene expression profiling. Blood 102, 2951–2959 (2003). 
70. Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL 
reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte 
differentiation and cell cycle progression. Leukemia 21, 1258–66 (2007). 
71. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute 
lymphoblastic leukaemia. Nature 446, 758–764 (2007). 
 42 
72. Kawamata, N. et al. Molecular allelokaryotyping of pediatric acute 
lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide 
genomic microarray. Blood 111, 776–84 (2008). 
73. Mullighan, C. G. et al. Deletion of IKZF1 and Prognosis in Acute 
Lymphoblastic Leukemia. N Engl J Med 360, 470–480 (2009). 
74. Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic 
leukaemia. Nature 471, 235–239 (2011). 
75. Dörge, P. et al. IKZF1 deletion is an independent predictor of outcome in 
pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. 
Haematologica 98, 428–432 (2013). 
76. Olsson, L. et al. Deletions of IKZF1 and SPRED1 are associated with poor 
prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic 
leukemia diagnosed between 1992 and 2011. Leukemia 28, 302–310 (2014). 
77. Öfverholm, I. et al. Impact of IKZF1 deletions and PAX5 amplifications in 
pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia (2013). 
doi:10.1038/leu.2013.92 
78. Kuiper, R. P. et al. IKZF1 deletions predict relapse in uniformly treated 
pediatric precursor B-ALL. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK (2010). 
doi:10.1038/leu.2010.87 
79. Chen, J., Odenike, O. & Rowley, J. D. Leukaemogenesis: more than mutant 
genes. Nat. Rev. Cancer 10, 23–36 (2010). 
80. Nordlund, J. et al. Genome-wide signatures of differential DNA methylation in 
pediatric acute lymphoblastic leukemia. Genome Biol. 14, r105 (2013). 
81. Nordlund, J. et al. DNA methylation-based subtype prediction for pediatric 
acute lymphoblastic leukemia. Clin. Epigenetics 7, (2015). 
82. Rieder, H. et al. dic(9;20): a new recurrent chromosome abnormality in adult 
acute lymphoblastic leukemia. Genes. Chromosomes Cancer 13, 54–61 (1995). 
83. Slater, R. et al. A non-random chromosome abnormality found in precursor-B 
lineage acute lymphoblastic leukaemia: dic(9;20)(p1?3;q11). Leukemia 9, 1613–1619 (1995). 
84. Heerema, N. A. et al. Dicentric (9;20)(p11;q11) identified by fluorescence in 
situ hybridization in four pediatric acute lymphoblastic leukemia patients. Cancer Genet. 
Cytogenet. 92, 111–115 (1996). 
85. Clark, R. et al. Monosomy 20 as a pointer to dicentric (9;20) in acute 
lymphoblastic leukemia. Leukemia 14, 241–6 (2000). 
 43 
86. Raimondi, S. C. et al. Reassessment of the prognostic significance of 
hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715–22 
(2003). 
87. Van Zutven, L. J. C. M. et al. CDKN2 deletions have no prognostic value in 
childhood precursor-B acute lymphoblastic leukaemia. Leukemia 19, 1281–1284 (2005). 
88. Jarosova, M. et al. Complex karyotypes in childhood acute lymphoblastic 
leukemia: cytogenetic and molecular cytogenetic study of 21 cases. Cancer Genet Cytogenet 
145, 161–8 (2003). 
89. Schoumans, J. et al. Characterisation of dic(9;20)(p11-13;q11) in childhood B-
cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative 
genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2. Br. J. Haematol. 
135, 492–499 (2006). 
90. Forestier, E. et al. Clinical and cytogenetic features of pediatric 
dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic 
series of 24 cases and review of the literature. Genes. Chromosomes Cancer 47, 149–158 
(2008). 
91. Strefford, J. C. et al. Genome complexity in acute lymphoblastic leukemia is 
revealed by array-based comparative genomic hybridization. Oncogene 26, 4306–18 (2007). 
92. An, Q. et al. Variable breakpoints target PAX5 in patients with dicentric 
chromosomes: A model for the basis of unbalanced translocations in cancer. Proc. Natl. 
Acad. Sci. 105, 17050–17054 (2008). 
93. An, Q. et al. Heterogeneous breakpoints in patients with acute lymphoblastic 
leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. 
Haematologica 94, 1164–1169 (2009). 
94. Kawamata, N. et al. Cloning of genes involved in chromosomal translocations 
by high-resolution single nucleotide polymorphism genomic microarray. Proc. Natl. Acad. 
Sci. 105, 11921 –11926 (2008). 
95. Mitelman, F., Johansson, B. & Mertens, F. Mitelman Database of Chromosome 
Aberrations and Gene Fusions in Cancer. (2015). at 
<http://cgap.nci.nih.gov/Chromosomes/Mitelman> 
96. Moorman, A. V. et al. Prognostic effect of chromosomal abnormalities in 
childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical 
Research Council ALL97/99 randomised trial. Lancet Oncol 11, 429–38 (2010). 
97. Pichler, H. et al. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell 
precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) 
protocols containing an intensive induction and post-induction consolidation therapy. Br. J. 
 44 
Haematol. 149, 93–100 (2010). 
98. Team, R. C. R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria, 2012. (ISBN 3-900051-07-0, 2012). 
99. Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation 
algorithm for the analysis of array CGH data. Bioinformatics 23, 657–663 (2007). 
100. Rasmussen, M. et al. Allele-specific copy number analysis of tumor samples 
with aneuploidy and tumor heterogeneity. Genome Biol. 12, R108 (2011). 
101. MacDonald, J. R., Ziman, R., Yuen, R. K. C., Feuk, L. & Scherer, S. W. The 
Database of Genomic Variants: a curated collection of structural variation in the human 
genome. Nucleic Acids Res. 42, D986–992 (2014). 
102. Neph, S. et al. BEDOPS: high-performance genomic feature operations. 
Bioinformatics 28, 1919–1920 (2012). 
103. Robinson, J. T. et al. Integrative genomics viewer. Nat Biotech 29, 24–26 
(2011). 
104. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinforma. Oxf. Engl. 25, 1754–1760 (2009). 
105. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 
15–21 (2013). 
106. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and 
scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013). 
107. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose 
program for assigning sequence reads to genomic features. Bioinforma. Oxf. Engl. 30, 923–
930 (2014). 
108. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential 
expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010). 
109. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock 
linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014). 
110. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. gkv007 (2015). 
doi:10.1093/nar/gkv007 
111. Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia 
with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125–134 
(2009). 
 45 
112. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based 
approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 
15545–15550 (2005). 
113. Kasprzyk, A. BioMart: driving a paradigm change in biological data 
management. Database 2011, bar049 (2011). 
114. Wu, D. et al. ROAST: rotation gene set tests for complex microarray 
experiments. Bioinforma. Oxf. Engl. 26, 2176–2182 (2010). 
115. DePristo, M. A. et al. A framework for variation discovery and genotyping 
using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011). 
116. McLaren, W. et al. Deriving the consequences of genomic variants with the 
Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070 (2010). 
117. Paila, U., Chapman, B. A., Kirchner, R. & Quinlan, A. R. GEMINI: Integrative 
Exploration of Genetic Variation and Genome Annotations. PLoS Comput Biol 9, e1003153 
(2013). 
118. Roberts, K. G. et al. Targetable Kinase-Activating Lesions in Ph-like Acute 
Lymphoblastic Leukemia. N. Engl. J. Med. 371, 1005–1015 (2014). 
119. Papaemmanuil, E. et al. RAG-mediated recombination is the predominant 
driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. 
Genet. (2014). doi:10.1038/ng.2874 
120. Nicorici, D. et al. FusionCatcher - a tool for finding somatic fusion genes in 
paired-end RNA-sequencing data. bioRxiv 011650 (2014). doi:10.1101/011650 
121. Lonnerholm, G. et al. Dic(9;20)(p13;q11) in childhood acute lymphoblastic 
leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids. 
Leukemia 23, 209–12 (2009). 
122. Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian 
of B cell identity and function. Nat Immunol 8, 463–470 (2007). 
123. Fortschegger, K., Anderl, S., Denk, D. & Strehl, S. Functional Heterogeneity of 
PAX5 Chimeras Reveals Insight for Leukemia Development. Mol. Cancer Res. 
molcanres.0337.2013 (2014). doi:10.1158/1541-7786.MCR-13-0337 
124. Strehl, S., Konig, M., Dworzak, M. N., Kalwak, K. & Haas, O. A. PAX5/ETV6 
fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 17, 1121–3 (2003). 
125. Schinnerl, D. et al. The role of the Janus-faced transcription factor PAX5-JAK2 
in acute lymphoblastic leukemia. Blood blood–2014–04–570960 (2014). doi:10.1182/blood-
2014-04-570960 
 46 
126. Kawamata, N., Pennella, M. A., Woo, J. L., Berk, A. J. & Koeffler, H. P. 
Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 31, 966–977 
(2012). 
127. Sulong, S. et al. A comprehensive analysis of the CDKN2A gene in childhood 
acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of 
heterozygosity, and association with specific cytogenetic subgroups. Blood 113, 100–107 
(2009). 
128. Waanders, E. et al. The Origin and Nature of Tightly Clustered BTG1 
Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of 
Multiclonal Evolution. PLoS Genet 8, e1002533 (2012). 
129. Paulsson, K. et al. Genetic landscape of high hyperdiploid childhood acute 
lymphoblastic leukemia. Proc. Natl. Acad. Sci. 107, 21719–21724 (2010). 
130. Raval, A. et al. Downregulation of Death-Associated Protein Kinase 1 
(DAPK1) in Chronic Lymphocytic Leukemia. Cell 129, 879–890 (2007). 
131. Meyer, L. H. et al. Early Relapse in ALL Is Identified by Time to Leukemia in 
NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways. 
Cancer Cell 19, 206–217 (2011). 
132. Holleman, A. et al. The expression of 70 apoptosis genes in relation to lineage, 
genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic 
leukemia. Blood 107, 769–776 (2006). 
 
